MPWT
RNA

MassMutual Private Wealth & Trust’s Atrium Therapeutics RNA Stock Holding History

MassMutual Private Wealth & Trust’s Portfolio RNA Stock Details RNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-2
Closed -$27 – 2534
2026
Q1 		$27 Buy
+2
New +$28 ﹤0.01% 2379

Other funds holding RNA

TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
CIEC
Crédit Industriel et Commercial Paris France, France $1.55B AUM 42.08% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
MWM
Moran Wealth Management Naples, Florida $3.67B AUM 36.71% 1-Year Est. Return
FI
Fractal Investments Glastonbury, Connecticut $867M AUM 23.63% 1-Year Est. Return
AA
AlphaCentric Advisors San Juan, Puerto Rico $118M AUM
KPWS
Kestra Private Wealth Services Austin, Texas $9.1B AUM 32.09% 1-Year Est. Return
CC
Corsicana & Co Corsicana, Texas $206M AUM 26.42% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

MassMutual Private Wealth & Trust's RNA Position: Q2 2026 in Review

MassMutual Private Wealth & Trust sold out of Atrium Therapeutics (RNA) in Q2 2026, closing a stake of 2 shares — an estimated $27 sold.

MassMutual Private Wealth & Trust first reported a position in RNA in Q1 2026 and held it in 1 quarter. The position peaked at $27 in Q1 2026. 34 funds tracked by Wall St. Rank hold RNA as of Q2 2026.

  • MassMutual Private Wealth & Trust reported no remaining Atrium Therapeutics position as of Q2 2026 after selling out during the quarter.
  • MassMutual Private Wealth & Trust sold 2 Atrium Therapeutics shares in Q2 2026, an estimated $27.
  • MassMutual Private Wealth & Trust first reported a position in Atrium Therapeutics in Q1 2026 and held it in 1 quarter.
  • MassMutual Private Wealth & Trust's Atrium Therapeutics position peaked at $27 in Q1 2026.
  • 34 funds tracked by Wall St. Rank held Atrium Therapeutics as of Q2 2026.

Based on MassMutual Private Wealth & Trust's 13F filing for Q2 2026, filed 2 Jul 2026.